Form 8-K - Current report:
SEC Accession No. 0001193125-25-109976
Filing Date
2025-05-01
Accepted
2025-05-01 16:13:37
Documents
14
Period of Report
2025-05-01
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d949809d8k.htm   iXBRL 8-K 29326
  Complete submission text file 0001193125-25-109976.txt   188357

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA plrx-20250501.xsd EX-101.SCH 3537
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE plrx-20250501_def.xml EX-101.DEF 13937
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE plrx-20250501_lab.xml EX-101.LAB 22899
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE plrx-20250501_pre.xml EX-101.PRE 14725
16 EXTRACTED XBRL INSTANCE DOCUMENT d949809d8k_htm.xml XML 6006
Mailing Address 331 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 331 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-481-6770
PLIANT THERAPEUTICS, INC. (Filer) CIK: 0001746473 (see all company filings)

EIN.: 474272481 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39303 | Film No.: 25903261
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)